Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:52:47.878Z.
Consensus retrieved: 2026-10-06T15:26:34.930Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:52:47.878Z.
Quote observation: 2026-10-06T18:50:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ed0d84ebe65fc765338e7baf7154c4548c52c7814b601df66b93f049f622236d
Forward PE Ratio (N/A) = Dated Quote Price ($3.57) / Consensus Forward EPS ($-0.97)
FORWARD PE RATIO
N/A
Prime Medicine, Inc.
Market Cap
$644.80M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Prime Medicine, Inc. (PRME) | $644.80M | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $636.13M | N/A |
| OmniAb, Inc. (OABI)vs › | $635.70M | N/A |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $629.87M | 9.61 |
| SOPHiA GENETICS S.A. (SOPH)vs › | $625.86M | N/A |
| Starling Oncology, Inc. (STLN)vs › | $656.34M | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $662.48M | N/A |
| Climb Bio, Inc. (CLYM)vs › | $618.02M | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $668.36M | N/A |
| Helus Pharma Inc. (HELP)vs › | $669.43M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $3.57, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.97 | $-1.11 – $-0.81 | 11 | n/m |
| 2027-12-31 | $-0.92 | $-1.11 – $-0.71 | 10 | n/m |
| 2028-12-31 | $-0.86 | $-1.15 – $-0.57 | 9 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
